News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

RaQualia Announces License Agreement with CJ CheilJedang for 5-HT4 Partial Agonist


7/29/2011 10:14:54 AM

AICHI, Japan--(BUSINESS WIRE)--RaQualia Pharma Inc. (RaQualia)(JASDAQ:4579)(ISIN:JP3967150008) today announced the signing of a license agreement with CJ CheilJedang Co. (CJ), granting CJ exclusive rights to develop, manufacture and commercialize RaQualia's 5-HT4 Partial Agonist (RQ-00000010) in Korea, China, Taiwan, India and Southeast Asia.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES